News & Events COVID-19

FDA Approves Initiation of Phase III Study of Lenzilumab in COVID-19 patients

April 15, 2020

Company intends to begin enrolling patients as soon as possible at several leading centers Phase III study enrollment to focus on adult, hospitalized patients with COVID-19 penumonia and at high risk of progression to respiratory failure ...

Read More

Media Coverage of CTI's COVID-19 Work

April 14, 2020

CTI One of Founding Contributers of NKY Coronavirus Emergency Relief Fund CTI is proud to be one of othe original contributers to a local relief fund for those affected by the pandemic. Coverage by the NKY Tribune Coverage by The Lane Report Coverage by the Cincinnati Enquirer CTI Partners ...

Read More

CTI Partners with Humanigen for Planned Phase III Study for Lenzilumab for Coronavirus Treatment

March 30, 2020

Study to tackle leading cause of death in COVID-19 patients Lenzilumab, a monoclonal antibody that neutralizes granulocyte macrophage colony stimulating factor (GM-CSF) GM-CSF is up-regulated in COVID-19 patients and may cause a harmful immune response leading to ...

Read More

How CTI Can Help Fight the Impact of COVID-19

March 27, 2020

What CTI Can Do to Help Fight the Impact of COVID-19 CTI is dedicated to helping our partners, team members, and communities work through the COVID-19 pandemic. Whether that means helping adjust programs impacted ...

Read More

Subscribe to our mailing list

* indicates required